Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.

Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, Teede HJ, Strickland AH, Allan CA.

Bone. 2013 Aug;55(2):305-8. doi: 10.1016/j.bone.2013.04.012. Epub 2013 Apr 25.

PMID:
23685544
[PubMed - indexed for MEDLINE]
2.

The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.

Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N, Giotis A, Sheehan P, Tsao M, Bedard G, Chow E.

Support Care Cancer. 2014 Jul;22(7):1765-71. doi: 10.1007/s00520-014-2142-2. Epub 2014 Feb 11.

PMID:
24515277
[PubMed - indexed for MEDLINE]
3.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Review.

PMID:
23706567
[PubMed - indexed for MEDLINE]
4.

Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.

Gulley JL, Wu S, Arlen PM, Dahut WL.

Clin Genitourin Cancer. 2007 Sep;5(6):403-5.

PMID:
17956715
[PubMed - indexed for MEDLINE]
5.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

PMID:
23049248
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?

Ho JW, Sundar S.

Clin Genitourin Cancer. 2012 Mar;10(1):50-3. doi: 10.1016/j.clgc.2011.11.004. Epub 2012 Jan 14. No abstract available.

PMID:
22245101
[PubMed - indexed for MEDLINE]
7.

[Inhibition of RANK ligand to treat bone metastases].

Body JJ.

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835. Review. French.

PMID:
24158618
[PubMed - indexed for MEDLINE]
8.

Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.

Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF.

Am J Emerg Med. 2013 Apr;31(4):756.e1-2. doi: 10.1016/j.ajem.2012.11.011. Epub 2013 Feb 8.

PMID:
23399342
[PubMed - indexed for MEDLINE]
9.

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

Fizazi K, Bosserman L, Gao G, Skacel T, Markus R.

J Urol. 2013 Jan;189(1 Suppl):S51-7; discussion S57-8. doi: 10.1016/j.juro.2012.11.022.

PMID:
23234632
[PubMed - indexed for MEDLINE]
10.

Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.

Vogelgesang SA, McMillin JM.

J Urol. 1988 Nov;140(5):1025-7.

PMID:
3172354
[PubMed - indexed for MEDLINE]
11.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
[PubMed - indexed for MEDLINE]
Free Article
12.

[Denosumab-induced severe hypocalcemia].

Barrasa Rodríguez MC, Ulla Anes M, Perez Rojas F, García Melcón G.

Med Clin (Barc). 2012 Jul 21;139(5):227-8. doi: 10.1016/j.medcli.2012.01.010. Epub 2012 Mar 6. Spanish. No abstract available.

PMID:
22397979
[PubMed - indexed for MEDLINE]
13.

Denosumab osteonecrosis of the mandible: a new entity? A case report.

Pichardo SE, Kuypers SC, van Merkesteyn JP.

J Craniomaxillofac Surg. 2013 Jun;41(4):e65-9. doi: 10.1016/j.jcms.2012.10.014. Epub 2012 Dec 21.

PMID:
23265807
[PubMed - indexed for MEDLINE]
14.

[The clinical merit of anti-RANKL antibody denosumab in prostate cancer].

Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S.

Gan To Kagaku Ryoho. 2012 Feb;39(2):207-12. Japanese.

PMID:
22333629
[PubMed - indexed for MEDLINE]
15.

Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.

Hanamura M, Iwamoto T, Soga N, Sugimura Y, Okuda M.

Biol Pharm Bull. 2010;33(4):721-4.

PMID:
20410614
[PubMed - indexed for MEDLINE]
Free Article
16.

Identification of the risk factors associated with hypocalcemia induced by denosumab.

Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K.

Biol Pharm Bull. 2013;36(10):1622-6. Epub 2013 Aug 9.

PMID:
23934346
[PubMed - indexed for MEDLINE]
Free Article
17.

Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.

Spencer S, Marini BL, Figg WD.

Anticancer Res. 2012 Jul;32(7):2391-8. Review.

PMID:
22753695
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies].

Todenhöfer T, Schwentner C, Schilling D, Gakis G, Stenzl A.

Urologe A. 2011 Sep;50(9):1055-63. doi: 10.1007/s00120-011-2623-6. Review. German. Erratum in: Urologe A. 2011 Oct;50(10):1322.

PMID:
21744161
[PubMed - indexed for MEDLINE]
19.

Severe symptomatic hypocalcaemia following a single dose of denosumab.

McLachlan JM, Marx GM, Bridgman M.

Med J Aust. 2013 Aug 19;199(4):242-3. No abstract available.

PMID:
23984777
[PubMed - indexed for MEDLINE]
20.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk